SCHEMBL22186264

SCHEMBL22186264

CC(C)(C)OC(=O)NC(=O)CCC(NC(=O)OC(C)(C)C)C(N)=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSK P43235 12/20 0.42
CTSS P25774 6/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
CAPN1 P07384 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
REN P00797 1/20 0.39
ACE P12821 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13263354 0.86 CTSK (0.44) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL14539642 0.84 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL22186262 0.84 SCN9A (0.44) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL14539748 0.84 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL7509222 0.84 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL8461423 0.84 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL10606976 0.84 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL27541323 0.84 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL20608551 0.83 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL11169650 0.83 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3618833-B1 TRIPARTITE ANDROGEN RECEPTOR ELIMINATORS, METHODS AND USES THEREOF SPG THERAPEUTICS INC (US) 2022-01-19 EP disclosed
US-20200207753-A1 Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof SPG THERAPEUTICS, INC. (US) 2020-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207753-A1 Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof AR, ESRRA, ESRRB CTSK 3019/4885CTSS 1412/4885CYP1A2 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.